An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists

Michael Koch, Christopher Steidle, Stanley Brosman, Arthur Centeno, Franklin Gaylis, Marilyn Campion, Marc B. Garnick

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives. To evaluate the ability of abarelix, a gonadotropin-releasing hormone antagonist, to provide an alternative treatment to bilateral orchiectomy in men with advanced prostate cancer symptoms and to evaluate its safety, clinical and biochemical efficacy, and effects on prostate-specific antigen and serum hormone levels. Methods. For 168 days, 81 patients from 17 centers received monthly intramuscular injections of open-label abarelix 100 mg (at least one dose). Patients were evaluated for the avoidance of bilateral orchiectomy, efficacy, disease response, percentage of change in prostate-specific antigen level, change in the intensity of pain, neurologic compromise, and other efficacy variables. Safety was evaluated through reports of adverse events and abnormal laboratory values. Results. No patients required bilateral orchiectomy, but 2 patients were withdrawn from the study because of treatment-related events and were considered as failures to avoid orchiectomy. Treatment produced an 88% (38 of 43) objective response rate on day 85. Sixty-five (90%) of 72 patients experienced improvement in the pain score and/ or analgesic use, urinary obstruction, urinary catheter removal, hydronephrosis, and/or azotemia. No patient with impending neurologic compromise at study entry developed spinal cord compression. The median reduction from the baseline prostate-specific antigen value was 75% on day 15 and greater than 95% from day 57 onward. Abarelix was well tolerated, and adverse events were the sequelae of advanced prostate cancer, comorbid medical disorders, or medical castration. Conclusions. These results suggest that abarelix provides a safe and effective medical alternative to surgical castration in symptomatic patients with advanced prostate cancer without the risk of the clinical flare associated with luteinizing hormone-releasing hormone agonists.

Original languageEnglish
Pages (from-to)877-882
Number of pages6
JournalUrology
Volume62
Issue number5
DOIs
StatePublished - Nov 2003

Fingerprint

Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Orchiectomy
Prostate-Specific Antigen
Castration
Nervous System
Therapeutics
Azotemia
Hormone Antagonists
Safety
Pain
Urinary Catheters
Spinal Cord Compression
Aptitude
Hydronephrosis
Intramuscular Injections
abarelix
Analgesics
Hormones
Serum

ASJC Scopus subject areas

  • Urology

Cite this

An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. / Koch, Michael; Steidle, Christopher; Brosman, Stanley; Centeno, Arthur; Gaylis, Franklin; Campion, Marilyn; Garnick, Marc B.

In: Urology, Vol. 62, No. 5, 11.2003, p. 877-882.

Research output: Contribution to journalArticle

Koch, M, Steidle, C, Brosman, S, Centeno, A, Gaylis, F, Campion, M & Garnick, MB 2003, 'An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists', Urology, vol. 62, no. 5, pp. 877-882. https://doi.org/10.1016/S0090-4295(03)00656-3
Koch, Michael ; Steidle, Christopher ; Brosman, Stanley ; Centeno, Arthur ; Gaylis, Franklin ; Campion, Marilyn ; Garnick, Marc B. / An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. In: Urology. 2003 ; Vol. 62, No. 5. pp. 877-882.
@article{21a069c1b8ae4278a9bcef18807990ec,
title = "An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists",
abstract = "Objectives. To evaluate the ability of abarelix, a gonadotropin-releasing hormone antagonist, to provide an alternative treatment to bilateral orchiectomy in men with advanced prostate cancer symptoms and to evaluate its safety, clinical and biochemical efficacy, and effects on prostate-specific antigen and serum hormone levels. Methods. For 168 days, 81 patients from 17 centers received monthly intramuscular injections of open-label abarelix 100 mg (at least one dose). Patients were evaluated for the avoidance of bilateral orchiectomy, efficacy, disease response, percentage of change in prostate-specific antigen level, change in the intensity of pain, neurologic compromise, and other efficacy variables. Safety was evaluated through reports of adverse events and abnormal laboratory values. Results. No patients required bilateral orchiectomy, but 2 patients were withdrawn from the study because of treatment-related events and were considered as failures to avoid orchiectomy. Treatment produced an 88{\%} (38 of 43) objective response rate on day 85. Sixty-five (90{\%}) of 72 patients experienced improvement in the pain score and/ or analgesic use, urinary obstruction, urinary catheter removal, hydronephrosis, and/or azotemia. No patient with impending neurologic compromise at study entry developed spinal cord compression. The median reduction from the baseline prostate-specific antigen value was 75{\%} on day 15 and greater than 95{\%} from day 57 onward. Abarelix was well tolerated, and adverse events were the sequelae of advanced prostate cancer, comorbid medical disorders, or medical castration. Conclusions. These results suggest that abarelix provides a safe and effective medical alternative to surgical castration in symptomatic patients with advanced prostate cancer without the risk of the clinical flare associated with luteinizing hormone-releasing hormone agonists.",
author = "Michael Koch and Christopher Steidle and Stanley Brosman and Arthur Centeno and Franklin Gaylis and Marilyn Campion and Garnick, {Marc B.}",
year = "2003",
month = "11",
doi = "10.1016/S0090-4295(03)00656-3",
language = "English",
volume = "62",
pages = "877--882",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists

AU - Koch, Michael

AU - Steidle, Christopher

AU - Brosman, Stanley

AU - Centeno, Arthur

AU - Gaylis, Franklin

AU - Campion, Marilyn

AU - Garnick, Marc B.

PY - 2003/11

Y1 - 2003/11

N2 - Objectives. To evaluate the ability of abarelix, a gonadotropin-releasing hormone antagonist, to provide an alternative treatment to bilateral orchiectomy in men with advanced prostate cancer symptoms and to evaluate its safety, clinical and biochemical efficacy, and effects on prostate-specific antigen and serum hormone levels. Methods. For 168 days, 81 patients from 17 centers received monthly intramuscular injections of open-label abarelix 100 mg (at least one dose). Patients were evaluated for the avoidance of bilateral orchiectomy, efficacy, disease response, percentage of change in prostate-specific antigen level, change in the intensity of pain, neurologic compromise, and other efficacy variables. Safety was evaluated through reports of adverse events and abnormal laboratory values. Results. No patients required bilateral orchiectomy, but 2 patients were withdrawn from the study because of treatment-related events and were considered as failures to avoid orchiectomy. Treatment produced an 88% (38 of 43) objective response rate on day 85. Sixty-five (90%) of 72 patients experienced improvement in the pain score and/ or analgesic use, urinary obstruction, urinary catheter removal, hydronephrosis, and/or azotemia. No patient with impending neurologic compromise at study entry developed spinal cord compression. The median reduction from the baseline prostate-specific antigen value was 75% on day 15 and greater than 95% from day 57 onward. Abarelix was well tolerated, and adverse events were the sequelae of advanced prostate cancer, comorbid medical disorders, or medical castration. Conclusions. These results suggest that abarelix provides a safe and effective medical alternative to surgical castration in symptomatic patients with advanced prostate cancer without the risk of the clinical flare associated with luteinizing hormone-releasing hormone agonists.

AB - Objectives. To evaluate the ability of abarelix, a gonadotropin-releasing hormone antagonist, to provide an alternative treatment to bilateral orchiectomy in men with advanced prostate cancer symptoms and to evaluate its safety, clinical and biochemical efficacy, and effects on prostate-specific antigen and serum hormone levels. Methods. For 168 days, 81 patients from 17 centers received monthly intramuscular injections of open-label abarelix 100 mg (at least one dose). Patients were evaluated for the avoidance of bilateral orchiectomy, efficacy, disease response, percentage of change in prostate-specific antigen level, change in the intensity of pain, neurologic compromise, and other efficacy variables. Safety was evaluated through reports of adverse events and abnormal laboratory values. Results. No patients required bilateral orchiectomy, but 2 patients were withdrawn from the study because of treatment-related events and were considered as failures to avoid orchiectomy. Treatment produced an 88% (38 of 43) objective response rate on day 85. Sixty-five (90%) of 72 patients experienced improvement in the pain score and/ or analgesic use, urinary obstruction, urinary catheter removal, hydronephrosis, and/or azotemia. No patient with impending neurologic compromise at study entry developed spinal cord compression. The median reduction from the baseline prostate-specific antigen value was 75% on day 15 and greater than 95% from day 57 onward. Abarelix was well tolerated, and adverse events were the sequelae of advanced prostate cancer, comorbid medical disorders, or medical castration. Conclusions. These results suggest that abarelix provides a safe and effective medical alternative to surgical castration in symptomatic patients with advanced prostate cancer without the risk of the clinical flare associated with luteinizing hormone-releasing hormone agonists.

UR - http://www.scopus.com/inward/record.url?scp=0242664216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242664216&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(03)00656-3

DO - 10.1016/S0090-4295(03)00656-3

M3 - Article

VL - 62

SP - 877

EP - 882

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -